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Abstract 
 
 Much of the improvement in the survival of individuals with cystic fibrosis (CF) is due to 
advancements in antimicrobial treatments. New aerosolized antibiotic formulations have recently 
been introduced (such as inhaled aztreonam), and others are in development (inhaled 
levofloxacin and liposomal amikacin). Licenced dry powder formulations include tobramycin 
inhalation powder and dry powder colistimethate (available in Europe). Although inhaled 
antibiotics have the advantage of being able to deliver high intrapulmonary concentrations of 
drug, antimicrobial resistance can still develop and is a concern in CF. Antimicrobial resistance 
might be mitigated by using non-antibiotic treatments, antibiotic adjuvants, which have activity 
against bacteria. Examples include agents such as gallium, antimicrobial peptides and anti-
biofilm compounds such as alginate oligosaccharides (OligoG) and garlic. Vaccination strategies 
and antibody therapy (IgY) against P. aeruginosa have also been attempted to prevent initial 
infection with this organism in CF. Although aggressive and long-term use of antibiotics has 
been crucial in slowing lung function decline and improving survival in people with CF, it has 
added a significant burden of care and associated toxicities in these individuals. Careful 
surveillance and the use of preventative strategies for antibiotic related toxicity (such as 
nephrotoxicity and ototoxicity) are essential. Continued development of effective antimicrobial 
agents that can function in the conditions encountered in the CF lung, such as against bacterial 
biofilm growth and under anaerobic conditions, is needed. 
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Introduction 
There has been significant improvement in the survival of individuals with cystic fibrosis 
(CF) over the last half century, from a median age of survival of 5 years in the 1970s to 
approximately 40 years of age as of 2011. The reasons for the improvement in clinical outcomes 
are multifactorial but include the intense use of antibiotic therapy in this patient population. 
Despite these improvements, however, the majority of CF deaths still occur in young adulthood, 
typically between the ages of 21-30 years (1). Continued development and optimal usage of new 
antimicrobial compounds (including antibiotic combinations) is essential to improve the quality 
and survival of people with CF.  
In the last several years, there have been an increasing number of available antibiotics, of 
different classes and formulations, for the treatment of pulmonary infections in CF patients. This 
review will discuss some of the new antibiotics including novel methods of delivery, the 
implications of the development of antimicrobial resistance, potential non-antibiotic treatments 
of CF lung infections and the lifetime burden and toxicity of repeated courses of antibiotic 
therapy. 
 
New antimicrobials and methods of delivery 
Several new inhalational antibiotics have recently become available for the treatment 
Pseudomonas aeruginosa pulmonary infections in CF patients (Table 1). Antibiotics delivered 
via aerosolization have the advantage of being able to achieve very high intrapulmonary 
concentrations with few associated systemic side effects.  
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Inhaled aztreonam 
Inhaled aztreonam, commercially known as AZLI or Cayston, is currently on the market 
for the treatment of Pseudomonas aeruginosa infections in CF patients. It is an aerosolized 
formulation of the monobactam antibiotic aztreonam and lysine. In contrast, the intravenous 
formulation of aztreonam contains arginine which can cause airway inflammation. The initial 
randomized controlled trial of inhaled aztreonam was performed in 211 individuals with CF 6 
years of age or older with P. aeruginosa infection (2).  After a 28 day course of tobramycin 
inhalation solution (TIS), patients were randomized to receive either 75 mg of inhaled aztreonam 
three times daily or placebo for 28 days. Inhaled aztreonam treatment increased the median time 
to requiring additional anti-pseudomonal antibiotics for symptoms of pulmonary exacerbation by 
21 days, compared with placebo (p=0.007). In addition, inhaled aztreonam improved mean 
symptom scores (p=0.02), forced expiratory volume in 1 second (FEV1) (6.3%, p=0.001) and 
sputum P. aeruginosa bacterial density (-0.66 log10 CFU/g, p=0.006) compared with placebo. 
The drug was well tolerated and the in vitro susceptibilities of P. aeruginosa isolates to 
aztreonam from baseline to end of therapy were comparable. Similar improvements in 
respiratory symptoms, lung function and microbiological outcomes were also observed in 
another Phase II trial of inhaled aztreonam in CF patients with moderate to severe lung disease 
and no recent use of anti-pseudomonal antibiotics or azithromycin (3). In CF individuals greater 
than 6 years of age and mild lung disease (FEV1>75% predicted), however, the effects of inhaled 
aztreonam treatment were more modest with no statistically significant improvement in 
respiratory symptoms and only a 2.7% improvement in relative FEV1% predicted (p=0.021) 
compared to placebo treatment (4). When compared to TIS in an open-label, parallel-group 
international trial in 273 patients with CF, after 3 cycles of inhaled aztreonam (28 day on; 28 
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days off), the mean change in FEV1 was 2.05% for aztreonam compared to -0.66% for TIS 
(p=0.002) (5). Patients in the aztreonam arm also had fewer respiratory hospitalizations and 
additional anti-pseudomonal antibiotics compared to the TIS arm. However, it is important to 
note that over 85% of subjects had already received at least 3 cycles of TIS before randomization 
and the beneficial effects of inhaled tobramycin are known to diminish over time. This so-called 
honeymoon effect is not restricted to aminoglycosides and is not explained by the development 
of in vitro resistance (6). In addition to studies in CF patients with P. aeruginosa infection, the 
efficacy of inhaled aztreonam has been examined in CF individuals with chronic Burkholderia 
cepacia complex infection (7). A double-blind, placebo-controlled, 24 week trial of continuous 
inhaled aztreonam versus placebo treatment was performed in 100 CF patients with chronic 
Burkholderia spp. infection. By 24 weeks of treatment, there was no significant difference 
between arms in terms of change in FEV1, number of respiratory exacerbations or 
hospitalizations. Importantly, there was also no significant decrease in sputum bacteria density 
change in treated patients compared to placebo. In vitro studies have demonstrated that 
aztreonam, as a ß-lactam that functions best against rapidly dividing organisms, may not have 
very good activity against CF organisms when grown as a biofilm, in contrast to 
aminoglycosides, for example (8). 
 
Levofloxacin inhalation solution 
Aerosolized levofloxacin is another new pharmaceutical agent developed for the teatment 
of P. aeruginosa pulmonary infections in patients with CF. Levofloxacin is a second generation 
fluoroquinolone that causes cell death by inhibiting topoisomerase, an enzyme required for DNA 
synthesis (9). It has properties that render it particularly effective against bacterial infections in 
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the CF lung. Thickened mucus layers in the lung of CF patients have been shown to contain 
areas of low oxygen tension, for example (10). In vitro studies of the effect of oxygen limitation 
on antimicrobial activity against P. aeruginosa demonstrate that, unlike tobramycin, amikacin 
and aztreonam, P. aeruginosa minimum inhibitory concentration (MICs) and time-kill curves for 
levofloxacin are similar under aerobic and anaerobic conditions (11). The same investigators 
have confirmed that, in comparison to aztreonam and aminoglycosides, levofloxacin has the 
most rapid rate of killing among P. aeruginosa isolates, is more potent against P. aeruginosa 
biofilms and its bactericidal activity is not affected by sputum (12). Additional in vitro studies 
have suggested that inhaled levofloxacin may also have anti-inflammatory effect (13). 
Levofloxacin produced a dose-dependent reduction of both TNF-α and P. aeruginosa 
lipopolysaccharide-induced IL-6 and IL-8 levels in cultured human airway epithelial cells. Phase 
I studies of safety, tolerability and pharmacokinetic parameters of inhaled levofloxacin in stable 
CF patients showed the drug to be safe, resulting in low serum levels (approximately 16% of 
serum levels after an oral dose). This should result in a very low risk of systemic toxicities such 
as tendinopathy or arthropathy. However, very high sputum concentrations were achieved, in the 
order of 4,000 µg/ml  (14).  A subsequent phase II randomized, placebo controlled study of 151 
CF patients with P. aeruginosa infection demonstrated that inhaled levofloxacin 240 mg twice 
daily for 28 days (delivered via eFlow nebulizer) resulted in an 8.7% increase in FEV1 percent 
predicted compared to placebo (p=0.003) (15). A phase III, open-label, randomized non-
inferiority study comparing  inhaled levofloxacin 240 mg twice daily versus tobramycin 
inhalation solution 300 mg twice daily over three 28 day on/off cycles in 282 CF patients with 
chronic P. aeruginosa infection demonstrated no significant difference in the change in FEV1% 
predicted between the groups (16). In addition, although there was no significant difference 
7	  
	  
between the groups in time to symptom-defined exacerbation, subjects treated with inhaled 
levofloxacin solution had a longer time to adminstration of antibiotics (p=0.04) and a lower 
proportion of subjects hospitalized for a respiratory exacerbation (p=0.04) than those treated with 
inhaled tobramycin. The number of adverse events were similar between the two groups; 
dysgeusia (taste distortion) was the most common adverse event in the inhaled levofloxacin 
group. 
 
Tobramycin inhalation powder 
In addition to new types of antibiotics of differing classes, there have also been 
developments in the way these drugs are formulated and delivered. A currently available 
example is tobramycin inhalation powder (TIP). New developments in particle manufacturing 
have allowed tobramycin to now be formulated as a dry powder. Tobramycin inhalation powder 
(TIP) has the advantages of being able to be delivered very quickly (in approximately 5 minutes) 
using a “podhalerTM” inhalation device and having good lung delivery (17). Initial 
pharmacokinetic studies demonstrated that TIP could achieve higher maximal sputum 
concentrations (measured 30 minutes after TIP administration) (1,092+1,052 µg/g) compared to 
TIS (737+1,028 µg/g), although with a wide standard deviation (18). In the phase III EVOLVE 
trial, TIP (112 mg twice daily) was compared to placebo in CF patients chronically infected with 
P. aeruginosa (19).  In comparison to placebo, TIP significantly improved FEV1, reduced 
sputum P. aeruginosa density and decreased respiratory related hospitalization. The most 
common adverse event was cough but this was higher in patients receiving placebo (26%) versus 
TIP (13%). TIP was not associated with ototoxicity or nephrotoxicity. Subsequently, the EAGER 
trial was conducted: a non-inferiority study to assess the safety and efficacy of TIP (112 mg 
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twice daily) compared to TIS (300 mg/5 ml twice daily) in chronic P. aeruginosa infected CF 
patients (20). TIP was comparable to TIS with similar increases in FEV1 and similar rates of 
hospitalizations for respiratory-related events. Sputum P. aeruginosa density was reduced more 
in TIP-treated patients relative to TIS-treated patients (-1.6 log10 vs -0.92 log10 CFU/g for 
mucoid isolates and -1.77 log10 vs -0.73 log10 CFU/g for nonmucoid isolates). In addition, TIP 
achieved higher mean sputum concentrations (measured 30 minutes post dose) than TIS 
(1979+2770 µg/g vs 1074+1182 µg/g).  The most common adverse event reported was cough 
which was higher in TIP (25%) than TIS (4%) treated patients. However, the rate of 
bronchospasm, nephrotoxicity, ototoxicity and serious adverse events were similar in both 
groups. 
 
Colistin inhalation powder 
Colistimethate sodium (colistin), a cationic polypeptide antibiotic (a polymyxin) which 
functions by disrupting the bacterial cell membrane, can also be delivered as a dry powder. It is 
commercially known as Colobreathe dry powder for inhalation. Colobreathe is an encapsulated 
dry-powder formulation administered using a hand-held inhaler (Turbospin). Colobreathe comes 
as capsules containing the equivalent of 125 mg colistimethate sodium (1 662 500 IU) in fine 
particle form. One inhaled capsule delivers the equivalent of a nebulised dose (> 2 MU). A Phase 
II, randomized open-label study was conducted in CF patients ages 6 years and older with 
chronic P. aeruginosa infection (21). After at least two 28 days of on-off TIS cycles, 380 
subjects were randomized to either one capsule of Colobreathe dry powder for inhalation twice 
daily (without interruption) or three 28 day cycles of TIS (300 mg/5 ml) delivered via PARI 
nebulizer twice daily for a total study duration of 24 weeks. After 24 weeks, the adjusted mean 
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difference between Colobreathe versus TIS in change in FEV1% predicted was -0.97% (95% CI -
2.74% to 0.86%), favouring TIS. This did not exceed the preset non-inferiority limit of the 95% 
CI (-3%). Few colistin-resistant P. aeruginosa isolates emerged and adverse events were similar 
in both groups. Although more patients in the Colobreathe group rated their device as easy to use 
compared to the TIS group, the improvement in lung function over the 6 month study period was 
negligible in both treatment arms.  
 
Inhaled liposomal amikacin 
Another novel method of delivery is the packaging of antibiotics within liposomes for 
aerosolization. An example of this is inhaled liposomal amikacin, otherwise known as Arikace. 
Arikace contains high concentrations of aqueous, water soluble amikacin, an aminoglycoside, 
encased within a liposome (22). The liposome is composed of 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC) and cholesterol which makes it very similar to surfactant, allowing it to 
be cleared from the lungs through a common pathway (22). Because the liposome is very small 
and has a neutral charge (shielding the positively charged amikacin from the negatively charged 
CF sputum), the drug is able to effectively penetrate into CF sputum and bacterial biofilms (23). 
Once at the site of infection, liposomes release the active drug, amikacin, upon exposure to 
rhamnolipids, a by-product of the P. aeruginosa bacteria itself. Phase I studies were done in 24 
CF patients with chronic P. aeruginosa infection who received 500 mg of liposomal amikacin by 
inhalation via the PARI LC STAR nebulizer once daily for 14 days (24). The relative change 
from baseline in forced expiratory volume in 1 second (FEV1) % predicted was 10.8% (p<0.001) 
and 5.62% (p=0.073) on days 7 and 14, respectively. However, there was no statistically 
significant change in the sputum P. aeruginosa bacterial density.  Follow up Phase II studies 
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were then performed comparing multi-dose Arikace delivered via eFlow nebulizer to placebo for 
28 days in CF patients with chronic P. aeruginosa infection (25). Overall, Arikace was well 
tolerated. Subjects receiving 280 mg of Arikace once daily had an increase in FEV1 from 
baseline of 0.10+0.128 L compared to an increase of 0.011+0.101 L (p=0.009) in the placebo 
group. Patients receiving 560 mg Arikace had an FEV1 increase from baseline of 0.081+0.161 L 
compared to 0.011+0.101 L (p=0.033) in the placebo group and this increase was maintained at 
day 56, even after 28 days off study drug (0.093+0.203 L vs -0.032+0.119 L, p=0.003). Mean P. 
aeruginosa sputum density was also significantly reduced in this treatment group at day 14, day 
28 and even at day 35 (7 days off treatment). A Phase III randomized, open label trial comparing 
Arikace to TIS in CF patients with P. aeruginosa infection has recently been completed but the 
results have not yet been published (clinicaltrials.gov identifier NCT01315678). In addition, the 
ability to deliver drug into biofilm structures within CF sputum may be beneficial in treating 
other multidrug resistant pathogens in CF such as Mycobacterium abscessus. A Phase II trial 
(clinicaltrials.gov identifier NCT01315236) is currently underway, in collaboration with the 
National Institute of Allergy and Infectious Diseases (NIAID), to study the use of Arikace for the 
treatment of recalcitrant nontuberculous mycobacteria lung disease in both CF and non-CF 
patients. 
 
Implications of antimicrobial resistance 
 
Definition of resistance and effects of sub-inhibitory drug concentrations 
Current definitions of bacterial resistance rely on antibiotic concentrations achieved by 
systemic therapy (oral or intravenous drug administration).  “Breakpoints’ by which resistance is 
11	  
	  
defined by the Clinical Laboratory Standards Institute (CLSI) are therefore generally quite low, 
requiring, for example, a minimum inhibitory concentration (MIC) of tobramycin of < 4 µg/ml 
for a P. aeruginosa isolate to be deemed susceptible (26). However, aerosolized antibiotics can 
achieve significantly higher sputum concentrations than intravenous antibiotics, in the order of 
100 fold greater (27). Thus, the clinically relevant definitions of resistance based on nebulized 
delivery have yet to be determined (28).  
Although aerosolized antibiotics have the advantage of being able to deliver high 
intrapulmonary concentrations of drug, antimicrobial resistance can still develop. There can be 
areas of atelectasis and mucous plugging causing certain areas of the CF lung to be under-
ventilated resulting in sub-inhibitory concentrations of antibiotics. Sub-inhibitory concentrations 
of antibiotics have been shown to increase the mutation frequency for P. aeruginosa as well as 
promote the formation of biofilm, leading to the selection of antimicrobial resistance (29). This is 
particularly true in the case of systemic administration of antibiotics, where the pulmonary drug 
concentrations are even lower, often far below the minimum inhibitory concentrations for 
organisms such as P. aeruginosa. However, certain antimicrobials such as azithromycin have 
been shown to have effects against P. aeruginosa even at sub-inhibitory concentrations. Sub-
inhibitory azithromycin concentrations can suppress motility and the production of several 
virulence factors, including proteases, pyocyanin, exotoxin A, phospholipase C and 
exopolysaccharides as well as the production of quorum sensing signal molecules (30).  
 
Consequences of antimicrobial resistance 
Antimicrobial resistance may still be relevant in CF and has potential clinical 
implications. Although in vitro antimicrobial susceptibility testing, whether done on planktonic 
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(31) or biofilm (32) growth of bacteria, has been shown not to correlate with clinical outcomes, 
greater drops in sputum bacterial density of P. aeruginosa do correlate, albeit to varying degrees, 
with increases in FEV1 (33). In addition, the development of antimicrobial resistance contributes 
to the persistence of bacteria within the CF lung and chronic infection with pathogens such as P. 
aeruginosa, Stenotrophomonas maltophilia and methicillin-resistant Staphylococcus aureus 
(MRSA), is associated with worse clinical outcomes (34-36). Finally, there is evidence to 
suggest that CF patients infected with multi-drug resistant organisms have worse survival 
following lung transplantation (37). 
The development of antimicrobial resistance is a particular problem in the long-term 
treatment of chronic CF pulmonary infections due to pathogens such as nontuberculous 
mycobacteria. Infection with bacteria of the M. abscessus complex, consisting of M. abscessus, 
M. bolletti and M. massiliense, are the most concerning, associated with more rapid lung function 
decline and death in CF (38-39). Empiric therapy often consists of a macrolide such as 
azithromycin or clarithromycin, an aminoglycoside such as amikacin and cefoxitin 
intravenously. However, M. abscessus subspecies abscessus often have an erythromycin 
ribosomal methylation (erm) gene which encodes for enzymes that methylate the 23S ribosomal 
RNA within the 50S ribosomal subunit, thus reducing the affinity of macrolides for their specific 
target in impairing protein synthesis (40).	   Although expression of the erm gene can be variable, 
its detection though molecular methods would preclude the use of a macrolide based regimen in 
the treatment of these infections. Even in the absence of the erm gene, M. abscessus species may 
resistant to macrolides through other mechanisms, such as efflux pumps (41). In vitro 
antimicrobial susceptibility testing can involve delays, however, requiring incubation of M. 
abscessus isolates with macrolides for 14 days to detect inducible mechanisms of resistance. A 
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more rapid, molecular technique that could detect all the genes encoding mechanisms of 
antimicrobial resistance within a bacterial genome has potential future clinical applications. 
 
Effects on the microbiome 
Antibiotics not only have effects on the predominant bacterial pathogen in an individual’s 
lung, but also on the multitude of other species that are known to exist as part of the CF lung 
microbiome. Changes in the microbiome in one location of the body, such as the gut, may even 
influence the bacterial composition in the lung (42). It is now well recognized that the CF 
pulmonary microbiota is composed of a diverse polymicrobial community that interact with one 
another and are influenced by repeated, spectrum courses of antimicrobial therapy (43). 
Organisms that are not routinely identified on CF cultures, such as anaerobes, have been shown, 
not surprisingly, to have reduced susceptibility to antibiotics typically used to treat CF patients 
(44). In a study of adult CF patients, cultured Prevotella isolates were significantly more 
resistant in vitro to amoxicillin-clavulanate and doxycycline than isolates from healthy adults 
(45). Use of antibiotics is the primary driver of decreased microbiome diversity in the CF lung 
(46). In an analysis of the effect of antibiotic use on microbial diversity in CF, intravenous 
antibiotic use, rather than oral or inhaled, had the highest probability of effecting greater change 
in community diversities, presumably due to the type of antibiotic used (eg. meropenem), with 
wide spectrums of action (47). Several investigators have studied the changes in the composition 
of the pulmonary microbiome at the onset of a CF exacerbation and have failed to identify any 
clear pattern to explain their occurrence (48-49). One group did observe an increase in the 
relative abundance of Gemella species at exacerbation, suggesting that this anaerobe may be 
involved in triggering a pulmonary exacerbation (50). Antimicrobial treatment of pulmonary 
14	  
	  
exacerbations has been associated with very early effects on the CF microbiome (as early as day 
3 of treatment) including significant reductions in the relative abundance of Pseudomonas which 
correlates with improvements in FEV1% predicted (51-52). In contrast, the decrease in anaerobic 
bacteria with antibiotic treatment in more variable and less strongly associated with 
improvements in lung function (52-53). Regardless, the pulmonary microbiome quickly returns 
to pre-treatment states following the end of antimicrobial treatment, indicating that it is quite 
resilient to change (49). Whether these combined results suggest inadequate treatment of 
dominant pathogens such as P. aeruginosa or potentially more appropriate, alternative targets 
such as anaerobes, is currently unknown. To answer these questions, further research, using large 
numbers of longitudinally collected samples at multiple time points with detailed corresponding 
antibiotic history, is required.           
 
Non-antibiotic treatments 
Antimicrobial resistance might be further prevented by using non-antibiotic treatments 
which have activity against bacterial species; these include the use of antibiotic adjuvants. These 
are a diverse group of novel agents which act by increasing the organism’s antibiotic 
susceptibility; by reducing its virulence; or by rendering the organism more susceptible to the 
host immune system (54). These include agents such as gallium, antimicrobial peptides and anti-
biofilm compounds. Additionally, vaccination strategies against P. aeruginosa have been 
attempted to prevent initial infection with this organism.  
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Gallium metal 
Gallium metal, structurally similar to iron (Fe), can substitute itself in many of the Fe 
dependent pathways essential in the growth and functioning of many bacteria such as P. 
aeruginosa (55). In such a way, gallium can inhibit the growth of bacteria such as P. aeruginosa. 
In vitro studies have shown that a liposomal gentamicin formulation with gallium metal is more 
effective than gentamicin alone in eradicating antibiotic-resistant P. aeruginosa isolates from CF 
patients, grown planktonically or as a biofilm (56). In fact, the liposomal gallium-gentamicin 
combination was the only formulation that completely eradicated biofilms and blocked quorum-
sensing molecules at very low concentrations of gentamicin (0.94 mg/L). Gallium is thus 
currently being investigated for its antibacterial properties and its potential applications in the 
treatment of pulmonary infections in CF.  
 
Antimicrobial peptides 
Another example of non-antibiotic compounds with antibacterial effects are antimicrobial 
peptides. Antimicrobial peptides, also known as defensins,  are endogenous peptides that are 
produced by myeloid and epithelial cells and are part of the innate immune system and the first 
line of host defense (57-58). Antimicrobial peptides disrupt the bacterial cell membrane causing 
lysis and death and thus have activity against a wide variety of microbial species (Gram-positive, 
Gram-negative organisms, fungi), attractive features in the treatment of CF pulmonary infections 
(59). Specific peptides such as cathelicidin peptides and lactoferrin have been shown to have 
activity against CF clinical isolates of P. aeruginosa and Burkholderia cepacia complex (60-61). 
However, despite their rapid and wide spectrum of activity, even mechanisms of resistance 
against antimicrobial peptides have been identified (62-63). 
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Anti-biofilm compounds 
Much of the difficulty encountered in treating pulmonary infections in CF patients is due 
to the fact that bacteria such as P. aeruginosa grow as a biofilm in the airways of CF patients 
with chronic pulmonary infections (64-65). When infection becomes chronic, Pseudomonas 
grow as biofilms; namely, bacterial populations embedded in a complex matrix comprising 
exopolysaccharide (bacterial alginate), airway mucins and neutrophil-derived DNA. The 
biosynthesis and regulation of bacterial alginate (which influences the architecture of the 
biofilm) is complex and involves mutations in bacterial regulatory genes (muc mutations) and an 
important population-based regulatory system known as quorum sensing (QS) (66-68). The 
quorum-sensing genes (LasR and RhlR) encode for virulence factors such as proteases, 
rhamnolipids, hemolysins, iron-scavenging pigments, catalase and superoxide dismutase (69). 
Biofilms are highly resistant to killing by antibiotics for many reasons.  This antimicrobial 
resistance is due in part to the polysaccharide matrix which retards the diffusion of antibiotics, 
but more importantly results in a slow rate of bacterial growth within the matrix, and in the case 
of aminoglycosides, to electrolyte interference with antibiotic activity (70).	  Much work has 
therefore been done to develop compounds that	  can inhibit or disrupt bacterial biofilms to allow 
antibiotics to work. An example of this is alginate oligosaccharides (OligoG), a biopolymer 
which is found in brown algae. In vitro studies have demonstrated that OligoG can not only 
inhibit biofilm formation and disrupt established 24-hour biofilms but also potentiate antibiotic 
effects, decreasing the minimum inhibitory concentration (MIC), up to 512-fold, for macrolides, 
β-lactams and tetracyclines, against important multidrug resistant pathogens such as P. 
aeruginosa and B. cepacia complex (71). Although its mechanism of action is not yet fully 
understood, it is postulated that it disrupts the bacterial membrane by chelating cations, allowing 
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antibiotics to effectively penetrate the cell. Phase II studies of inhaled dry powder OligoG in 
adult patients with CF are currently underway (clinicaltrials.gov identifier NCT02157922). 
Another potentially useful anti-biofilm agent is garlic and garlic extracts, in particular, the 
compounds allicin and ajoene. Using high-throughput screening, garlic was discovered to inhibit 
quorum sensing through a presently unknown mechanism (72). When P. aeruginosa was grown 
in vitro in continuous-culture flow chambers, the garlic-treated biofilms, in comparison to 
untreated controls, were susceptible to both tobramycin and polymorphonuclear leukocyte killing 
(73). In addition, in a mouse model of P. aeruginosa pulmonary infection, the treated group had 
a greater decrease in lung bacterial burden compared to the placebo group. When tested in a trial 
of 26 CF patients, there was a greater decline in FEV1 from baseline for patients in the placebo 
arm compared to the garlic treated arm and a greater increase in weight in the garlic treated arm 
compared to the placebo arm, although neither of these differences between treatment groups 
was significant (74). With this suggestion of improvement with garlic treatment, larger trials 
investigating its potential benefit in CF are warranted. The potential value of trials of natural 
products, either alone or, more likely, as adjuvants to present antimicrobial therapy, has recently 
been emphasized by the killing potential of pure allicin and allicin-containing aqueous garlic 
extract against the Burkholderia cepacia complex, a multiresistant and life-threatening pathogen 
for which there are few treatments (75). Another potential advance in the treatment of 
Burkholderia, comes from deliberately targeting the organism's unusual lipopolysaccharide and 
demonstration of the potent antimicrobial properties of the novel LPS inhibiting agent, CHIR090 
(76). 
 
Immunization against P. aeruginosa  
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Given the intrinsic difficulties in treating established P. aeruginosa chronic infections in 
the CF lung, preventing initial infection through immunization is an attractive alternative. 
Multiple attempts have been made to develop vaccines using different antigenic components of 
the P. aeruginosa bacterium, including outer membrane proteins, surface polysaccharides and 
flagellar proteins. Antibody studies done in CF patients have demonstrated that IgG, IgM and 
IgA against P. aeruginosa whole cell and specific outer membrane proteins can be detected in 
serum and bronchoalveolar lavage fluid following both upper and lower respiratory tract 
infection, suggesting potential vaccine antigens (77). Surface polysaccharides are another 
possible antigenic option but polysaccharides such as alginate, which is a conserved antigen 
across many P. aeruginosa strains, is poorly immunogenic in humans and does not induce the 
production of protective antibodies. In an effort to boost its immunogenicity, P. aeruginosa 
polysaccharides have been conjugated to toxins as well as flagellar proteins as vaccines (78-79). 
Yearly immunization with O-polysaccharide-toxin A conjugate vaccine against P. aeruginosa in 
25 CF patients induced sustained but low levels of vaccine-specific serum IgG antibodies (79). 
In contrast, P. aeruginosa flagella vaccines produce high and long-lasting serum antibody titers 
against flagella antigens (80). In the largest randomized, placebo controlled trial of a bivalent 
flagella P. aeruginosa vaccine in 483 CF patients, the vaccine produced high and long-lasting 
serum antiflagella IgG titers (81). After 4 intramuscular vaccinations, the relative risk of P. 
aeruginosa infection in the per-protocol group was 0.66 (95% CI: 0.46-0.93, p=0.02) compared 
to placebo, indicating that vaccination provided a 34% degree of protection (82). Of note, some 
vaccinated patients were infected with P. aeruginosa strains that expressed flagella antigens not 
included in the vaccine, suggesting that a multivalent flagella vaccine preparation may be 
required. Although the results of this vaccine trial appeared promising, another randomized, 
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double-blind controlled trial conducted by industry (Aerugen Berna Vaccine) of a polyvalent 
(exotoxin-A-polysaccharide) Pseudomonas vaccine in 476 participants was prematurely 
terminated with no reported results, raising the concern of publication bias as noted in a 
Cochrane review (83). Detecting the efficacy of P. aeruginosa vaccines in clinical trials may 
have also been affected by the increasing and, in some centers, continuous use of one or more 
nebulized antibiotics, and a reduced frequency of exacerbations. Thus, although immunization 
against P. aeruginosa in CF patients cannot yet be recommended (83), it bears promise that 
deserves ongoing investigation. Mucosal immunization, reflecting the actual route of infection, 
may be more effective than intramuscular or subcutaneous vaccination. P. aeruginosa 
vaccination in 48 healthy volunteers demonstrated a significant rise in IgA and IgG in the lower 
airways only after nasal and oral, not systemic, vaccination (84). In addition, prophylaxis against 
P. aeruginosa infection using anti-P. aeruginosa antibodies has also been tried in CF. Gargling 
with anti-Pseudomonas IgY, isolated from the egg yolks of hens immunized with P. aeruginosa, 
has been shown to decrease the number of P. aeruginosa infections in a small number of 
individuals with CF (85), presumably by preventing initial colonization of the organism in the 
oropharynx. A phase III study to evaluate the clinical efficacy and safety of avian polyclonal 
anti-Pseudomonas antibodies (IgY) in the prevention of recurrence of P. aeruginosa infection in 
CF patients is currently underway (clinicaltrials.gov identifier NCT01455675). At present, there is 
no commercially-available anti-pseudomonal vaccine. 
 
Lifetime antimicrobial burden and toxicity 
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Burden of care and adherence 
Although the repeated and long-term use of antibiotics has been crucial in slowing lung 
function decline and improving survival in people with CF, it has added a significant burden of 
care in these individuals. In addition to pancreatic enzymes, vitamins, physiotherapy, inhaled 
mucolytics and possibly inhaled glucocorticoids and/or bronchodilators, patients may also be 
taking inhaled tobramycin, oral azithromycin, in addition to the prescribed oral and intravenous 
antibiotics for pulmonary exacerbations. CF patients with chronic P. aeruginosa infection are 
frequently on inhaled tobramycin for life, given that there are no clear guidelines or data as to 
when to stop this therapy. Furthermore, with the advent of other anti-pseudomonal inhaled 
antibiotics such as aztreonam, some patients are now being treated with a second aerosolized 
antibiotic in the “off month”of the tobramycin cycle as an attempt to maintain FEV1, adding to 
the complexity of their treatment plan. More rapid, efficient nebulizers and dry powder delivery 
systems such as the podhaler are helpful in terms of reducing the time required for patients to do 
their therapies and hopefully increasing their compliance and adherence. Adherence to therapies 
is an important component to the improvement of outcomes; high adherence with tobramycin 
inhalation solution, for example, has been shown to be associated with a decreased risk of 
hospitalization (86). Unfortunately, studies have demonstrated that only 32% of CF patients are 
fully adherent to prescribed nebulized antibiotic treatment (87). Chip-based recording nebulizers 
can store data such as treatment date, time, duration and completeness of dose, that can then be 
downloaded to generate an accurate report of adherence (88). Using this type of information, it is 
possible to provide patients with feedback and adjust treatment schedules to hopefully improve 
compliance (89).  
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Antimicrobial toxicities 
In addition to the burden of lifelong antimicrobial therapies, CF patients have to contend 
with the associated toxicities as well. These toxicities are most apparent for aminoglycosides, for 
which the primary side effects are nephrotoxicity and ototoxicity. Intravenous aminoglycosides 
are a mainstay of therapy for the treatment of pulmonary exacerbations in CF. Serum drug levels 
should be monitored to avoid nephrotoxicity. Given that aminoglycosides function in a 
concentration dependent manner, once daily dosing is likely to be more efficacious as well as 
associated with fewer toxicities (90). Minimizing long-term nephrotoxicity is important with 
respect to lung transplantation as well because renal impairment is a strong predictor of 
decreased survival following lung transplantation in CF (91). The ototoxicity seen with 
aminoglycosides can either be a sensorineural hearing loss or a vestibular toxicity and is 
associated with drug accumulation within the inner ear cells with prolonged use. For the 
treatment of nontuberculous mycobacterial pulmonary infections in individuals with CF, in 
which aminoglycosides such as amikacin are frequently used for a significant portion of the 
treatment course, intravenous administration should be limited to 4 weeks with the remainder of 
the therapy given through inhalation. Even with aerosolized administration of aminoglycosides, 
hearing loss has been reported in CF patients with prolonged use (92). In addition to the 
toxicities specifically seen with aminoglycoside use, other adverse events in CF patients from 
prolonged intravenous antimicrobial therapy include thromboses secondary to central catheter 
placement, for example.  
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Conclusions 
The advantages of aerosolized therapy suggest that this is an important area for future 
drug development.  Antimicrobials should also be designed to be effective in the conditions 
encountered in the CF lung such as against bacterial biofilm growth, under anaerobic conditions 
and be able to penetrate sputum. With the discovery of small molecules that can restore the 
function of the cystic fibrosis transmembrane conductance regulator (CFTR), it is hoped that one 
day individuals with CF will no longer be afflicted with these difficult to treat pulmonary 
infections caused by opportunistic, multidrug resistant pathogens. However, until the underlying 
defect can be corrected in all CF patients, antimicrobial treatments that decrease the bacterial 
contribution to the underlying pulmonary hyper-inflammatory state are vital to the quality of life 
and survival of individuals with CF.  
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